Ascendis Pharma is applying its innovative technology platform to build a leading, fully integrated biopharma company focused on making a meaningful difference in patients’ lives. Guided by our core values of patients, science, and passion, we use our TransCon® technology platform to create new and potentially best-in-class therapies.

Ascendis Pharma currently has three independent endocrinology rare disease product candidates in clinical development and is also advancing programs in Oncology and Ophthalmology. Ascendis is headquartered in Copenhagen, Denmark, and has additional offices in Heidelberg, Munich, and Berlin in Germany; Palo Alto and Redwood City, California; and Princeton, New Jersey in the United States.

For more information about Ascendis, please visit us at ascendispharma.com or follow Ascendis on Twitter and LinkedIn.